Praluent (alirocumab) website for UK Patients

Printed From:

Website intended for UK residents prescribed with Praluent

Patient Information Leaflets

Type

A A A

Print

Patient Information Leaflets

Home
About Praluent
- What is Cholesterol?
- What is Praluent?
Starting Praluent
- Using Praluent
- Your Praluent pen
FAQs and Resources
- FAQs
- Glossary
- Resources

Keep learning about
Praluent and find the
support you need

We are here to provide information
and support throughout your
treatment journey

I have been prescribed Praluent 75mg or 150mg every 2 weeks

I have been prescribed Praluent 300mg every 4 weeks (monthly)

RESOURCES

Download educational booklets and find useful links about how to manage your cholesterol

FAQS

Find the answer to questions you may have about Praluent

PRALUENT PATIENTS

This website and its contents have been developed for UK residents prescribed with Praluent.

In order to proceed into the website, please confirm that you are, or you care for, a UK resident prescribed with Praluent by clicking the confirmation button below.

Information intended for UK residents who are not prescribed Praluent can be found by clicking here.

Information intended for UK healthcare professionals can be found by clicking here.

MAT-GB-2003851 (v10.0) | June 2025

Leaving to HCP site

This site is intended for U.S. Healthcare Professionals only.

Do you wish to continue?

YOU ARE LEAVING THE PRALUENT UK WEBSITE

This link will take you to a website to which our Privacy Policy does not apply. Sanofi UK has no control over the contents of these sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them.

Click the "Continue" button below to go to the page you requested or click "Cancel" to remain on this page.

You are about to leave sanofi site for U.S.

Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

This site might not comply with the regulatory requirements of US

You are about to move to an Unbranded site

You are moving to an Unbranded site

Share this information with friends and family.

E-mail This Page to a Friend

Recipient's Name

Recipient's Email Address

Your Name

Your Email Address

Subject

Your friend has shared this page about WhiteSite

Send a copy to myself (optional)

Your Email Has Been Sent

Your email has been sent to:

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

By reporting side effects, you can help provide more information on the safety of this medicine.

Patient Information Leaflets

MAT-GB-2003851 (v10.0)
June 2025.

This website and its contents has been developed and funded by Sanofi.

The Sanofi Group conducts its business in the United Kingdom through its subsidiaries Sanofi-Synthelabo and Aventis Pharma LTD.

Legal

Privacy Policy
Terms of Use
Cookie Policy

©2025 Sanofi.
All rights reserved.